Dear Colleagues, I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on Section 232 Pharmaceutical Proclamation. “A thriving ...
WASHINGTON, D.C. - Brad Zakes, senior vice president for emerging companies and economic affairs at the Biotechnology Innovation Organization (BIO), released the following statement on passage of ...
Dear Mr. Thune, Mr. Schumer, Mr. Johnson, and Mr. Jeffries:As President and CEO of the Biotechnology Innovation Organization (BIO), as a father and entrepreneur whose family is here today because of ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement. “The passage of the Mikaela Naylon Give Kids a Chance Act is ...
WASHINGTON, DC (January 7th, 2026) – Today, the Biotechnology Innovation Organization (BIO) announced the launch of the BIO Investment Council (BIC). The newly established council aims to serve small ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA ...
WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...
It's Day 4. We recap a few impactful sessions exploring why patients – including rare disease patients and women – can't wait. Today, we close out with a look at how we can ensure the virtuous cycle ...
WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results